TENX TENAX THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, TENAX THERAPEUTICS INC reported revenue of n/a, net income of −$17.8M and diluted EPS of −$0.35; for the fiscal year ended December 2025 revenue was $0.
TENX annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $0, gross profit n/a, operating income −$56.4M, net income −$52.6M (margin n/a), EPS −$1.34
- Fiscal year ended Dec 2024: revenue $0, gross profit n/a, operating income −$19.5M, net income −$17.6M (margin n/a), EPS −$1.15
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$8.23M, net income −$7.70M (margin n/a), EPS −$31.04
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income $11.1M, net income $11.0M (margin n/a), EPS n/a
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$32.7M, net income −$32.5M (margin n/a), EPS −$1.58
TENX quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$17.8M, EPS −$0.35
- Quarter ended Mar 31, 2026: revenue $0, net income −$15.7M, EPS −$0.35
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$15.5M, EPS −$0.39
- Quarter ended Sep 30, 2025: revenue n/a, net income −$15.8M, EPS −$0.40
- Quarter ended Jun 30, 2025: revenue n/a, net income −$10.8M, EPS −$0.27
- Quarter ended Mar 31, 2025: revenue $0, net income −$10.4M, EPS −$0.28
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$6.27M, EPS $3.99
- Quarter ended Sep 30, 2024: revenue n/a, net income −$3.96M, EPS −$0.19
- Quarter ended Jun 30, 2024: revenue n/a, net income −$3.58M, EPS −$1.83
- Quarter ended Mar 31, 2024: revenue n/a, net income −$3.80M, EPS −$3.12
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$7.16M, EPS n/a
- Quarter ended Sep 30, 2023: revenue n/a, net income $1.97M, EPS n/a
- Quarter ended Jun 30, 2023: revenue n/a, net income −$1.11M, EPS n/a
- Quarter ended Mar 31, 2023: revenue n/a, net income −$1.41M, EPS n/a
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income $13.7M, EPS n/a
- Quarter ended Sep 30, 2022: revenue n/a, net income $2.92M, EPS n/a
- Quarter ended Jun 30, 2022: revenue n/a, net income −$2.86M, EPS n/a
- Quarter ended Mar 31, 2022: revenue n/a, net income −$2.72M, EPS n/a
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$10.8M, EPS $0.31
- Quarter ended Sep 30, 2021: revenue n/a, net income $3.80M, EPS −$0.15
TENX cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$35.8M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$14.8M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$5.90M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$11.4M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$10.9M, share buybacks n/a
TENX balance sheet
- Jun 30, 2026: cash $118M, total assets $122M, total liabilities $8.07M, shareholders' equity $114M
- Mar 31, 2026: cash $119M, total assets $123M, total liabilities $8.49M, shareholders' equity $115M
- Dec 31, 2025: cash $97.6M, total assets $104M, total liabilities $7.16M, shareholders' equity $97.1M
- Sep 30, 2025: cash $99.4M, total assets $103M, total liabilities $6.60M, shareholders' equity $96.2M
- Jun 30, 2025: cash $106M, total assets $106M, total liabilities $2.53M, shareholders' equity $103M
- Mar 31, 2025: cash $111M, total assets $112M, total liabilities $2.77M, shareholders' equity $109M
- Dec 31, 2024: cash $94.9M, total assets $96.7M, total liabilities $4.69M, shareholders' equity $92.0M
- Sep 30, 2024: cash n/a, total assets $99.8M, total liabilities $2.56M, shareholders' equity $97.2M
What is TENX's revenue?
TENAX THERAPEUTICS INC reported $0 of revenue for the fiscal year ended December 2025.
Is TENX profitable?
No. TENAX THERAPEUTICS INC lost $64.9M over the last four quarters.
What is TENX's EPS?
Diluted earnings per share over the last four quarters were −$1.49; −$0.35 in the latest quarter.